PATIENT WEBSITE LINK:

https://studykik.com/study-page/wamd-20389-hcp

Study Site Locations

Please contact the site closest to you for study inquiries or to discuss a patient referral.

Search within
Miles of

AZ

Retinal Consultants of Arizona/ Retinal Reseach Institute

Neal Palejwala

15401 N. 29th Ave.

Phoenix

AZ

85053

Rebekah Bratton

602-977-6154

AR

Retina Partners of Northwest Arkansas

Serrhel Adams

601 West Maple Avenue Suite 205A

Springdale

AR

72764

Ethan Korpella

CA

Bay Area Retina Associates

Roger Goldberg

365 Lennon Ln. Suite 250 & 270

Walnut Creek

CA

94598

Ana Magsayo

CA

Macula and Retina Institute

Kent Small

411 N Central Ave Ste 115

Glendale

CA

91203

Amber Diaz

CO

Eye Center of Northern Colorado

Brittney Statler

3151 Precision Dr

Fort Collins

CO

80528

Andrea Lopez

CO

RSC Research, PLLC

Ross Chod

950 E. Harvard Ave Suite 530

Denver

CO

80210

Ronald Farmer

CT

Connecticut Eye Consultants, P.C.

Richard Scartozzi

69 Sand Pit Road Suite 101

Danbury

CT

06810

Mackenzee George

FL

Eye Associates of Pinellas

Jason Handza

9375 66th St N

Pinellas Park

FL

33782

Mariah Kilgore

FL

Retina Specialists of Tampa

Evan Dunn

2400 Cypress Glen Drive

Wesley Chapel

FL

33544

Tracy Warner

FL

Retina Specialty Institute

Sunil Gupta

5150 N Davis Hwy

Pensacola

FL

32503

Sarah Faruzzi

FL

Retina Vitreous Associates of Florida

Ashley Crane

12903 N 56th

Tampa

FL

33617

Ledra Bataku

MA

Ophthalmic Consultants of Boston

Chirag Shah

50 Staniford St Ste 600

Boston

MA

02114

Maria Jose Martinez Lopez

VA

The Retina Group of Washington

Alexander Melamud

8270 Willow Oaks Corporate Drive Suite 600

Fairfax

VA

22031

Rachel Rivera

MD

The Retina Care Center

Eric Suan

6115 Falls Road Suite 300

Baltimore

MD

21209

Amanda McGee

MI

Foundation for Vision Research

Thomas Aaberg

5030 Cascade Rd. SE

Grand Rapids

MI

49546

Eric Hederstedt

MI

Vitreoretinal Specialist, PLC.; DBA- Retina Associates of Michigan

Raafay Sophie

8562 Holly Rd.

Grand Blanc

MI

48439

Tracy Utley

MS

Deep Blue Retina Clinical Research PLLC

Jorge Calzada

7900 Airways Boulevard Building A, Suite 1

Southaven

MS

38671

Jen Cooper

NJ

NJ RETINA

Paul Hahn

628 Cedar Lane

Teaneck

NJ

07666

Emily Diaz Osorio

NJ

NJ Retina

Daniel Roth

530 Lakehurst Rd Suite 305

Toms River

NJ

08755

Dina Christodoro

OK

Tulsa Retina Consultant

Joaquin Tosi

2424 E. 21st Street Suite 200

Tulsa

OK

74114

Kim Sargent

OR

Verum Research LLC

Albert Edwards

1011 Valley River Way Suite 110

Eugene

OR

97401

Lillian Carroll

TX

San Antonio Eye Center

Gawain Dyer

511 Dallas St.

San Antonio

TX

78215

Tyler Kostopoulos

UT

Retina Associates of Utah

Robert Kwun

5169 S Cottonwood St Suite 630

Salt Lake City

UT

84107

Brittany Brewster

UT

Rocky Mountain Retina Consultants

Mitchel Goff

4400 South 700 East Suite #200

Salt Lake City

UT

84107

Donna Knight

UT

Salt Lake Retina

Andrew Davis

3855 W. 7800 South Suite #100

West Jordan

UT

84088

Tamara Sailors

VA

Piedmont Eye Center

Golnaz Javey

116 Nationwide Drive

Lynchburg

VA

24502

Susan Shelton

VA

Retina Associates, PC

Andrew McFarland

1901 Campus Blvd Suite 320

Winchester

VA

22601

Kaitlyn Poppo

MD

Retina Group of Washington

Michael Lai

5454 Wisconsin Ave Suite 650

Chevy Chase

MD

20815

Danielle Downer

eye charteye chart

Inclusion and Exclusion Criteria

Patients who meet the following criteria may be eligible to participate: Inclusion • Male or female subjects, ≥50 years of age. • Documented diagnosis of wAMD in the study eye, with onset of disease that began at any time prior to the Screening Visit. • Active subfoveal CNV due to wAMD, including juxtafoveal lesions that affect the fovea, as defined by presence of fluid (intraretinal or subretinal) affecting the central subfield as measured by SD-OCT. Exclusion • CNV caused by ocular histoplasmosis, pathological myopia, angioid streaks, choroidal rupture, uveitis, and trauma. • Fibrosis >50% of the total lesion. This is not a full list of criteria.

FAQ’s

What is the primary objective of the EYP-1901-301 study?

To evaluate the efficacy of EYP-1901 intravitreal (IVT) insert on best corrected visual acuity (BCVA) changes compared to aflibercept treatment.

What is the study drug being evaluated in the EYP-1901-301 study?

EYP-1901 (vorolanib intravitreal [IVT] insert)

If my patient qualifies for the EYP-1901-301 study, will they receive the study drug?

Participants will be randomly assigned to one of two treatment groups: EYP-1901 or aflibercept.

How many participants will be in this study?

Approximately 400 participants will be enrolled.

Created by StudyKIK